Burnell Thomas W. reported option exercise involving 1,966,763 derivative units of INTERPACE BIOSCIENCES, INC. at $0.00 for $0 on Aug 20, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CEO, President & Chairman
CEO, President & Chairman
Filed Aug 20, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
1,966,763Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Aug 20, 2026Option exercise
Filed
Aug 20, 2026, 5:59 PM ET0-day reporting delay
Accession
0001493152-26-039528Code M · Transaction 14329
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 20, 2026Option exercise1,966,763$0.00$0Trade 14326
Aug 20, 2026Grant554,018$0.00$0Trade 14330
Aug 20, 2026Tax withholding581,718$1.61−$936,565.98Trade 14327
Aug 20, 2026Grant1,966,763$0.00$0Trade 14328
5 transaction rows in this filing. Joint filers share the same rows.

IDXG price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IDXG · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Aug 27, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents the conversion upon vesting of restricted stock units ("RSUs") into shares of common stock of Interpace Biosciences, Inc. (the "Issuer"). On August20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award. F2: Represents shares returned to the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person received the net number of shares after the shares were returned to the Issuer to satisfy applicable tax withholding obligations. F3: Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc. F4: On August 20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award. F5: The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.